Baoji Pharmaceutical is a biopharmaceutical R&D manufacturer, a Sino-foreign joint biopharmaceutical enterprise integrating drug R&D and production. The company can produce recombinant protein drugs and recombinant antibody drugs on a large scale, focusing on providing innovative and disruptive solutions for clinical needs. Recently, Baoji Pharmaceuticals completed a Series B financing of over US$100 million. The financing was led by Dongfang Fuhai, followed by Haitong Innovation, Shengshi Capital, and additional investment from old shareholders Center Lab and Yuanchuang Capital. It is mainly used to promote the commercialization of core products under development and the key clinical trials of new pipelines. .
This article is reproduced from: https://www.itjuzi.com/investevent/13508289
This site is for inclusion only, and the copyright belongs to the original author.